页数:22页文件大小:379.5 KB来源: 药理学ppt课件
本课件为药理学课程中的《第二章药物代谢动力学》,围绕第二章药物代谢动力学、Routes of Drug、清除率(ml、时间 CAB 血药浓度等部分展开,逐页梳理概念、机制与临床应用要点,适合预习、课堂对照与考前复习。
第二章药物代谢动力学 Pharmacokinetics
Transformation Free Systemic Circulation Bounddrug Freedrug Metabolites Locus of Action“receptors”Bound Free Tissue Reservoirs Bound Exceretion Absorption
Acrossmembraneand lipid Acrossaqueouschannel Carrier-mediatedtransport Outside Inside Manners of Transport Across Membrance Passive transport
Routes of Drug Administration Enteralwithin or by way of the GI tract Oral (PO), rectal, sublingual Parenteral Not within the alimentary canal Inhalation, IM, SC, IP, topical Central Into the brain or spinal cord Intrathecal
Routes of Drug Administrationcommon abbreviations…PO =per os= oral IV = intravenous = into the vein IM = intramuscular = into the muscle SC = subcutaneous = between the skin and muscle IP = intraperitoneal = within the peritoneal cavityicv = intracerebroventricular =directly into the ventricle of the brain
Factors Affecting Response to Drugs Dosage Route of Administration Rate of Absorption Rate of Elimination Physiochemical properties of the drugage, sex, species, metabolism, etc…
清除率(ml/min)5040302010002468020400120153001234567 苯巴比妥[弱酸性药](狗)苯丙胺[弱碱性药](人)精神反应血浆药物浓度尿排泄量酸性尿(p H~5)碱性尿(p H~7)碱性尿 p H7.8-8.0 酸性尿 p H<7 排尿(ml/min)mmol/hm M 计分值尿 p H 值对药物排泄的影响
0204060801001200246810 血浆阿司匹林浓度(mg/L)时间(min)口服和静脉注射阿司匹林 659mg 后的时-量曲线
时间 CAB 血药浓度 MEC 三种不同的生物利用度 A.吸收速度快、吸收量完全 B.吸收速度与 A 相同,但吸收量仅为 A 的 50%C.吸收量完全,但吸收速度为 A 的 50%
血浆地高辛浓度(nmol/L)12345012 四种由不同药厂生产的相同剂量地高辛片剂的生物利用度时间(h)
Eliminationkinetics1. First-ordereliminationkinetics
0210123456 稳态浓度药物浓度 Css.max Css.min7 多次给药的时-量曲线
血药浓度 100200300802460002468100200300 时间(半衰期)10020030002460ABC8MTCMEC 三种不同给药方案对稳态浓度的影响 A.缩短给药时间 B.增加给药剂量 C.负荷量给药
2. Zero-ordereliminationkinetics
Pharmacokinetic Evaluation of Gepirone Immediate
Release Capsulesand Gepirone Extended
Release Tablets in Healthy Volunteers JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 92, NO. 9, SEPTEMBER 2003
Gepirone is a 5-HT1Aagonist forthe treatment of major depression.
half-life of3 h and good oralbioavailability, and undergoesextensive first-pass metabolism
Because of its rapid absorption andshort half-life, the gepirone-IR(immediate-release formulation) must beadministered at least twice daily.
This regimen results in high peakconcentrations and marked peak-to-trough fluctuations in plasmaconcentrations.
These fluctuations may contribute to anincreased incidence of adverse events,such asnausea, dizziness, headache, andsomnolence, andhave the potential toresult in lower patient compliance andreduced effectiveness.
extended-release gepirone formulation(ER)immediate-release formulation(IR)
Figure 1. Mean gepirone plasma concentrationsfollowing administration of gepirone-IR formulations(10mgq12 h,n=12) or gepirone-ER formulations (ER-1:20 mg q24 h, n=12; ER-2: 20 mg q24 h, n=12; ER-3:25 mg q24 h, n=12).
Figure 2. Mean 1-PP plasma concentrations followingadministration of gepirone-IR formulations(10 mg q12 h, n=12) or gepirone-ER formulations (ER-1: 20 mg q24 h, n=12; ER-2: 20 mg q24 h, n=12; ER-3:25 mg q24 h, n=12).
下载地址:{{downurl}}
{{{a}}}
{{#b}}{{{b}}}
{{/b}} {{/title}} {{#nolog}}登陆注册
{{/nolog}} {{#djsx}}点我刷新
{{/djsx}} {{#gocz}} {{/gocz}} {{#ffqr}} {{/ffqr}}